Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H19N7O |
| Molecular Weight | 397.4326 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC=C1N2C(=O)C3=C(C=CC=C3C)N=C2CN4C=NC5=C4N=CN=C5N
InChI
InChIKey=GNWHRHGTIBRNSM-UHFFFAOYSA-N
InChI=1S/C22H19N7O/c1-13-6-3-4-9-16(13)29-17(27-15-8-5-7-14(2)18(15)22(29)30)10-28-12-26-19-20(23)24-11-25-21(19)28/h3-9,11-12H,10H2,1-2H3,(H2,23,24,25)
| Molecular Formula | C22H19N7O |
| Molecular Weight | 397.4326 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/19689267
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/19689267
IC87114 is a PI3K-delta-specific inhibitor, which inhibits PI3K-delta 58-fold more potently than PI3K-gamma, and over 100-fold more potently than PI3K-alpha and PI3K-beta. Pharmacological investigations on IC87114 originally focused on its effect against inflammation and autoimmune diseases. IC87114 treatment dramatically blocked amphetamine-induced hyperlocomotion, suggestive of antipsychotic potential. In addition, IC87114 exhibited promising therapeutic effect in a murine asthma model.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3130 |
0.5 µM [IC50] | ||
Target ID: CHEMBL3267 |
29.0 µM [IC50] | ||
Target ID: CHEMBL3145 |
75.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. | 2012-07 |
|
| Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. | 2012-05 |
|
| Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. | 2009-02-01 |
|
| Interleukin 13 increases contractility of murine tracheal smooth muscle by a phosphoinositide 3-kinase p110delta-dependent mechanism. | 2008-05 |
|
| Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. | 2006-01-15 |
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:49:09 GMT 2025
by
admin
on
Mon Mar 31 22:49:09 GMT 2025
|
| Record UNII |
9HC746B1KF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
371242-69-2
Created by
admin on Mon Mar 31 22:49:09 GMT 2025 , Edited by admin on Mon Mar 31 22:49:09 GMT 2025
|
PRIMARY | |||
|
9HC746B1KF
Created by
admin on Mon Mar 31 22:49:09 GMT 2025 , Edited by admin on Mon Mar 31 22:49:09 GMT 2025
|
PRIMARY | |||
|
DTXSID00190617
Created by
admin on Mon Mar 31 22:49:09 GMT 2025 , Edited by admin on Mon Mar 31 22:49:09 GMT 2025
|
PRIMARY | |||
|
9908783
Created by
admin on Mon Mar 31 22:49:09 GMT 2025 , Edited by admin on Mon Mar 31 22:49:09 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
